BRIEF-PolyPid Says D-PLEX (100) Meets Primary Efficacy Endpoint In Phase 3 Trial

Reuters

09 Jun

BRIEF-PolyPid Says D-PLEX (100) Meets Primary Efficacy Endpoint In Phase 3 Trial

June 9 (Reuters) - PolyPid Ltd PYPD.O:

POLYPID ANNOUNCES POSITIVE TOPLINE RESULTS FROM PHASE 3 SHIELD II TRIAL: D-PLEX₁₀₀ DEMONSTRATED SIGNIFICANT REDUCTION IN SURGICAL SITE INFECTIONS AND SUCCESSFULLY MET PRIMARY AND ALL KEY SECONDARY ENDPOINTS
POLYPID LTD - D-PLEX(100) MEETS PRIMARY EFFICACY ENDPOINT IN PHASE 3 TRIAL
POLYPID LTD - TO SUBMIT NDA TO FDA IN EARLY 2026
POLYPID LTD - TRIAL SHOWS 58% REDUCTION IN SURGICAL SITE INFECTIONS WITH D-PLEX(100)
POLYPID LTD - STUDY SHOWS 38% REDUCTION IN PRIMARY ENDPOINT EVENTS WITH D-PLEX(100)
POLYPID LTD - NO SAFETY CONCERNS RAISED BY INDEPENDENT DATA SAFETY MONITORING BOARD IN SHIELD II

Source text: ID:nGNX8tbD4K

Further company coverage: PYPD.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2542810013"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2542810013\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2542810013?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-09 20:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2542810013","market":"nz","top_or_hot":-1,"title":"BRIEF-PolyPid Says D-PLEX (100) Meets Primary Efficacy Endpoint In Phase 3 Trial","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-PolyPid Says D-PLEX (100) Meets Primary Efficacy Endpoint In Phase 3 Trial</title></head><body><p><span>June 9 (Reuters)</span><span> - </span>PolyPid Ltd <span>PYPD.O</span>:</p><ul><li><p>POLYPID ANNOUNCES POSITIVE TOPLINE RESULTS FROM PHASE 3 SHIELD II TRIAL: D-PLEX₁₀₀ DEMONSTRATED SIGNIFICANT REDUCTION IN SURGICAL SITE INFECTIONS AND SUCCESSFULLY MET PRIMARY AND ALL KEY SECONDARY ENDPOINTS</p></li><li><p>POLYPID LTD - D-PLEX(100) MEETS PRIMARY EFFICACY ENDPOINT IN PHASE 3 TRIAL</p></li><li><p>POLYPID LTD - TO SUBMIT NDA TO FDA IN EARLY 2026</p></li><li><p>POLYPID LTD - TRIAL SHOWS 58% REDUCTION IN SURGICAL SITE INFECTIONS WITH D-PLEX(100)</p></li><li><p>POLYPID LTD - STUDY SHOWS 38% REDUCTION IN PRIMARY ENDPOINT EVENTS WITH D-PLEX(100)</p></li><li><p>POLYPID LTD - NO SAFETY CONCERNS RAISED BY INDEPENDENT DATA SAFETY MONITORING BOARD IN SHIELD II</p></li></ul><p>Source text: <span>ID:nGNX8tbD4K</span></p><p>Further company coverage: <span>PYPD.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-PolyPid Says D-PLEX (100) Meets Primary Efficacy Endpoint In Phase 3 Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-PolyPid Says D-PLEX (100) Meets Primary Efficacy Endpoint In Phase 3 Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-06-09 20:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-PolyPid Says D-PLEX (100) Meets Primary Efficacy Endpoint In Phase 3 Trial</title></head><body><p><span>June 9 (Reuters)</span><span> - </span>PolyPid Ltd <span>PYPD.O</span>:</p><ul><li><p>POLYPID ANNOUNCES POSITIVE TOPLINE RESULTS FROM PHASE 3 SHIELD II TRIAL: D-PLEX₁₀₀ DEMONSTRATED SIGNIFICANT REDUCTION IN SURGICAL SITE INFECTIONS AND SUCCESSFULLY MET PRIMARY AND ALL KEY SECONDARY ENDPOINTS</p></li><li><p>POLYPID LTD - D-PLEX(100) MEETS PRIMARY EFFICACY ENDPOINT IN PHASE 3 TRIAL</p></li><li><p>POLYPID LTD - TO SUBMIT NDA TO FDA IN EARLY 2026</p></li><li><p>POLYPID LTD - TRIAL SHOWS 58% REDUCTION IN SURGICAL SITE INFECTIONS WITH D-PLEX(100)</p></li><li><p>POLYPID LTD - STUDY SHOWS 38% REDUCTION IN PRIMARY ENDPOINT EVENTS WITH D-PLEX(100)</p></li><li><p>POLYPID LTD - NO SAFETY CONCERNS RAISED BY INDEPENDENT DATA SAFETY MONITORING BOARD IN SHIELD II</p></li></ul><p>Source text: <span>ID:nGNX8tbD4K</span></p><p>Further company coverage: <span>PYPD.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250609:nTUA2VNPCC:1","article_id":"2542810013","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2542810013","pubTimestamp":1749470597,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-PolyPid Says D-PLEX (100) Meets Primary Efficacy Endpoint In Phase 3 TrialJune 9 (Reuters) - PolyPid Ltd PYPD.O:POLYPID ANNOUNCES POSITIVE TOPLINE RESULTS FROM PHASE 3 SHIELD II TRIAL: D-PLEX DE","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","PYPD":"PolyPid Ltd."},"translate_title":"BRIEF-PolyPid表示D-PLEX(100)在3期试验中达到了主要疗效终点","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PYPD":0.9},"content_text":"BRIEF-PolyPid Says D-PLEX (100) Meets Primary Efficacy Endpoint In Phase 3 TrialJune 9 (Reuters) - PolyPid Ltd PYPD.O:POLYPID ANNOUNCES POSITIVE TOPLINE RESULTS FROM PHASE 3 SHIELD II TRIAL: D-PLEX₁₀₀ DEMONSTRATED SIGNIFICANT REDUCTION IN SURGICAL SITE INFECTIONS AND SUCCESSFULLY MET PRIMARY AND ALL KEY SECONDARY ENDPOINTSPOLYPID LTD - D-PLEX(100) MEETS PRIMARY EFFICACY ENDPOINT IN PHASE 3 TRIALPOLYPID LTD - TO SUBMIT NDA TO FDA IN EARLY 2026POLYPID LTD - TRIAL SHOWS 58% REDUCTION IN SURGICAL SITE INFECTIONS WITH D-PLEX(100)POLYPID LTD - STUDY SHOWS 38% REDUCTION IN PRIMARY ENDPOINT EVENTS WITH D-PLEX(100)POLYPID LTD - NO SAFETY CONCERNS RAISED BY INDEPENDENT DATA SAFETY MONITORING BOARD IN SHIELD IISource text: ID:nGNX8tbD4KFurther company coverage: PYPD.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}